Your browser doesn't support javascript.
loading
RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.
Matthijssens, Filip; Sharma, Nitesh D; Nysus, Monique; Nickl, Christian K; Kang, Huining; Perez, Dominique R; Lintermans, Beatrice; Van Loocke, Wouter; Roels, Juliette; Peirs, Sofie; Demoen, Lisa; Pieters, Tim; Reunes, Lindy; Lammens, Tim; De Moerloose, Barbara; Van Nieuwerburgh, Filip; Deforce, Dieter L; Cheung, Laurence C; Kotecha, Rishi S; Risseeuw, Martijn Dp; Van Calenbergh, Serge; Takarada, Takeshi; Yoneda, Yukio; van Delft, Frederik W; Lock, Richard B; Merkley, Seth D; Chigaev, Alexandre; Sklar, Larry A; Mullighan, Charles G; Loh, Mignon L; Winter, Stuart S; Hunger, Stephen P; Goossens, Steven; Castillo, Eliseo F; Ornatowski, Wojciech; Van Vlierberghe, Pieter; Matlawska-Wasowska, Ksenia.
Afiliación
  • Matthijssens F; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Sharma ND; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Nysus M; Department of Pediatrics, Division of Hematology-Oncology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
  • Nickl CK; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
  • Kang H; Department of Pediatrics, Division of Hematology-Oncology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
  • Perez DR; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
  • Lintermans B; Department of Pediatrics, Division of Hematology-Oncology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
  • Van Loocke W; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
  • Roels J; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
  • Peirs S; Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
  • Demoen L; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
  • Pieters T; University of New Mexico Center for Molecular Discovery, Albuquerque, New Mexico, USA.
  • Reunes L; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Lammens T; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • De Moerloose B; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Van Nieuwerburgh F; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Deforce DL; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Cheung LC; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Kotecha RS; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Risseeuw MD; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Van Calenbergh S; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Takarada T; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Yoneda Y; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • van Delft FW; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Lock RB; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Merkley SD; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Chigaev A; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Sklar LA; Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
  • Mullighan CG; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Loh ML; Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
  • Winter SS; Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.
  • Hunger SP; Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.
  • Goossens S; Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
  • Castillo EF; School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Western Australia, Australia.
  • Ornatowski W; Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
  • Van Vlierberghe P; School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Western Australia, Australia.
  • Matlawska-Wasowska K; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
J Clin Invest ; 131(6)2021 03 15.
Article en En | MEDLINE | ID: mdl-33555272
ABSTRACT
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with inferior outcome compared with that of B cell ALL. Here, we show that Runt-related transcription factor 2 (RUNX2) was upregulated in high-risk T-ALL with KMT2A rearrangements (KMT2A-R) or an immature immunophenotype. In KMT2A-R cells, we identified RUNX2 as a direct target of the KMT2A chimeras, where it reciprocally bound the KMT2A promoter, establishing a regulatory feed-forward mechanism. Notably, RUNX2 was required for survival of immature and KMT2A-R T-ALL cells in vitro and in vivo. We report direct transcriptional regulation of CXCR4 signaling by RUNX2, thereby promoting chemotaxis, adhesion, and homing to medullary and extramedullary sites. RUNX2 enabled these energy-demanding processes by increasing metabolic activity in T-ALL cells through positive regulation of both glycolysis and oxidative phosphorylation. Concurrently, RUNX2 upregulation increased mitochondrial dynamics and biogenesis in T-ALL cells. Finally, as a proof of concept, we demonstrate that immature and KMT2A-R T-ALL cells were vulnerable to pharmacological targeting of the interaction between RUNX2 and its cofactor CBFß. In conclusion, we show that RUNX2 acts as a dependency factor in high-risk subtypes of human T-ALL through concomitant regulation of tumor metabolism and leukemic cell migration.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Subunidad alfa 1 del Factor de Unión al Sitio Principal / Leucemia-Linfoma Linfoblástico de Células T Precursoras Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Child / Humans Idioma: En Revista: J Clin Invest Año: 2021 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Subunidad alfa 1 del Factor de Unión al Sitio Principal / Leucemia-Linfoma Linfoblástico de Células T Precursoras Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Child / Humans Idioma: En Revista: J Clin Invest Año: 2021 Tipo del documento: Article País de afiliación: Bélgica